Deutsche Bank downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $68. after Stryker (SYK) entered into a definitive agreement to acquire Inari Medical for $4.9B in cash. The deal is expected to close by end of Q1 and given the “highly complementary” nature of Inari’s portfolio, regulatory approvals should be expeditious, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: